Cary Street Partners’s Roivant Sciences ROIV Stock Holding History

Cary Street Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,162	Closed	-$281K	–	1114
2026 Q1	$281K	Buy	+10,162	New	+$261K	0.01%	731

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Cary Street Partners's ROIV Position: Q2 2026 in Review

Cary Street Partners sold out of Roivant Sciences (ROIV) in Q2 2026, closing a stake of 10,162 shares — an estimated $281K sold.

Cary Street Partners first reported a position in ROIV in Q1 2026 and held it in 1 quarter. The position peaked at $281K in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Cary Street Partners reported no remaining Roivant Sciences position as of Q2 2026 after selling out during the quarter.
Cary Street Partners sold 10,162 Roivant Sciences shares in Q2 2026, an estimated $281K.
Cary Street Partners first reported a position in Roivant Sciences in Q1 2026 and held it in 1 quarter.
Cary Street Partners's Roivant Sciences position peaked at $281K in Q1 2026.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.